Who
Todd Anderman
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Ocular Therapeutix.
In numbers
- Trades disclosed
- 8
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $225K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 Oct 2024
- Last trade
- 8 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Oct 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Oct 2026filed 13 Oct 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $87K11,984 at $7.29 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —64,900 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —197,650 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —197,650 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —64,900 at $0.00 | filing |
| 8 Oct 2025filed 10 Oct 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $137K11,132 at $12.34 | filing |
| 7 Oct 2024filed 9 Oct 2024 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —296,500 at $0.00 | filing |
| 7 Oct 2024filed 9 Oct 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —98,700 at $0.00 | filing |
News
Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Todd Anderman Sells 11,984 Sharesthemarketsdaily.com · 15 Oct 2026Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Todd Anderman Sells 11,984 SharesOCUL · themarketsdaily.com · 15 Oct 2026Ocular Therapeutix (NASDAQ:OCUL) Upgraded to Strong-Buy at UBS GroupOCUL · dailypolitical.com · 14 Oct 2026Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)OCUL · dailypolitical.com · 13 Oct 2026
1 headline in the last 90 days name Todd Anderman; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.